An observational study in Cervical Cancer Susceptible Population Classification, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-09.
Sponsored by Anhui Provincial Hospital · Observational
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.
Anhui Provincial Hospital is the lead sponsor of 131 studies on the registry; 97 are open to participants now.
Counted across the registry records on this site, refreshed daily.
HPV positive person at average risk of cervical cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
HPV negative, TCT negative
Genetic: PCR and sequence
HPV postive, TCT: CIN I or Colposcopy LSIL
Genetic: PCR and sequence
HPV postive, TCT: CIN II-III or Colposcopy HSIL
Genetic: PCR and sequence
HPV positive, Histopathology: cervical cancer
Genetic: PCR and sequence
sequence the mutatation SNPs
Evalutaiton of the SNPs test in an average cervical cancer patients screening episode
Time frame: two years
Classified susceptied person into different ladders
Time frame: two years
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.